Treatment for Peritoneal Metastasis of Patients With Colorectal Cancer

From the perspective of survival outcomes, the cancer survival of colorectal cancer (CRC) in the whole stage has improved. Peritoneal metastasis (PM) is found in approximately 8% to 15% of patients with CRC, with a poorer prognosis than that associated with other sites of metastases. Randomized controlled trials and up-to-date meta-analyses provide firm evidence that cytoreductive surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC) could significantly improve overall survival compared with systemic chemotherapy alone in selected patients with CRC-PM. Practical guidelines recommend that the management of CRC-PM should be led by a multidisciplinary team carried out in experienced centers and consider CRS plus HIPEC for selected patients. In this review, we aim to provide the latest results of land mark studies and an overview of recent insights with regard to the management of CRC-PM.

Automated summary

Colorectal cancer peritoneal metastasis (CRC-PM) is found in 8% to 15% of patients with CRC and has a poor prognosis. Cytoreductive surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC) significantly improves overall survival in selected patients. Management of CRC-PM should be carried out by experienced multidisciplinary teams in specialized centers.